Welcome!

News Feed Item

Cytox starts clinical evaluation of novel mTOR blood tests for dementia

Cytox Ltd, (Cytox) a leading developer of assays for risk assessment and prediction of dementia, announced the start of two landmark exploratory clinical trials designed to evaluate a new blood assay platform that could potentially assist in the evaluation of an individual’s risk for dementia and Alzheimer’s.

The two studies will obtain samples from patients in Europe and in the United States. One study will identify mTOR dysregulation in well-characterized patients who are either cognitively normal or who have been diagnosed with probable Alzheimer’s disease, Fronto-temporal Lobe Dementia (FTLD) or Dementia with Lewy bodies (DLB).

The other study will evaluate the performance of the assay platform in patients with mild cognitive impairment assessing the relationship between the assay output (mTOR dysregulation) and the presence or absence, using Positron Emission Tomography (PET) imaging, of amyloid plaques in the brain, a hallmark pathology of Alzheimer’s disease. First results are expected toward the end of this year.

Blood samples from up to 370 patients will be obtained in clinical centers of excellence across the European Union and in the United States and sent for analysis by Cytox’s laboratory in Manchester, UK. Samples in the United States are being collected in a recently established partnership between Cytox and Selah Genomics of Greenville, South Carolina.

Commenting on the start of the clinical programme, one of the study investigators, Professor Bruno Dubois of the Neurological Institute of the Salpétrière University Hospital in Paris, France, said that, “While we are making real progress in identifying biomarkers of established disease, there is still a need for the earliest possible signal that dementia is a risk in individual patients. If we see a relationship between assessment of the mTOR pathway and clinical outcome with this assay platform, such information could help research and eventually better patient management.”

Professor Harald Hampel, Excellence Chair and another of the investigators at Pierre and Marie Curie University (Sorbonne), Paris, further commented, “To find effective solutions to prevent the growing global Alzheimer epidemic we need to develop supportive biological markers of the disease. Finding suitable blood-based biomarkers would be most appealing since they are non-invasive, clinically generalizable across all healthcare sectors and can benefit patients across all regions in the world."

Dr. Richard Pither, CEO of Cytox, said, “This is an innovative clinical program for a novel potential risk marker of dementia. The science behind mTOR’s role in the pathogenesis of Alzheimer’s and other dementias is extensive and from this science, our assay platform can potentially yield important practical clinical applications to help the fight against this significant public health problem.”

Dr. Pither explains further that, “These milestones have enabled our own research as well as opening up potential future collaborations with academic research and the Pharmaceutical industry. In partnership with research into other biomarkers and new drug approaches, we hope to play a significant role in tackling the scourge of dementias such as Alzheimer’s disease.”

About Cytox Limited

Cytox Limited is a UK company researching into the role of mTOR pathway dysfunction and the associated development of prognostic tests for cognitive decline and risk of developing AD or other dementias. Cytox has exclusive rights to build on the discoveries made by the company's scientific founder, Dr. Zsuzsanna Nagy of cell cycle-related biomarkers associated with the risk of developing dementia. The company is developing her work and assessing its significance in trials and will be looking to work with pharmaceutical partners to develop our understanding of the technology and its role in drug development.

For more about the mTOR pathway and its potential role in early identification of risk of Dementia and Alzheimer’s disease, follow this link: www.cytoxgroup.com/information-for-editors

Visit our website at www.cytoxgroup.com

https://www.facebook.com/cytoxdx
https://twitter.com/CytoxDx
http://www.linkedin.com/company/cytox-limited

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Rapid innovation, changing business landscapes, and new IT demands force businesses to make changes quickly. In the eyes of many, containers are at the brink of becoming a pervasive technology in enterprise IT to accelerate application delivery. In this presentation, attendees learned about the: The transformation of IT to a DevOps, microservices, and container-based architecture What are containers and how DevOps practices can operate in a container-based environment A demonstration of how ...
Cloud Expo, Inc. has announced today that Andi Mann returns to 'DevOps at Cloud Expo 2017' as Conference Chair The @DevOpsSummit at Cloud Expo will take place on June 6-8, 2017, at the Javits Center in New York City, NY. "DevOps is set to be one of the most profound disruptions to hit IT in decades," said Andi Mann. "It is a natural extension of cloud computing, and I have seen both firsthand and in independent research the fantastic results DevOps delivers. So I am excited to help the great t...
SYS-CON Events announced today that Fusion, a leading provider of cloud services, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Fusion, a leading provider of integrated cloud solutions to small, medium and large businesses, is the industry’s single source for the cloud. Fusion’s advanced, proprietary cloud service platform enables the integration of leading edge solutions in the cloud, including clou...
Fact: storage performance problems have only gotten more complicated, as applications not only have become largely virtualized, but also have moved to cloud-based infrastructures. Storage performance in virtualized environments isn’t just about IOPS anymore. Instead, you need to guarantee performance for individual VMs, helping applications maintain performance as the number of VMs continues to go up in real time. In his session at Cloud Expo, Dhiraj Sehgal, Product and Marketing at Tintri, sha...
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Phil Hombledal, Solution Architect at CollabNet, discussed how customers are able to achieve a level of transparency that e...
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
"Venafi has a platform that allows you to manage, centralize and automate the complete life cycle of keys and certificates within the organization," explained Gina Osmond, Sr. Field Marketing Manager at Venafi, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Get deep visibility into the performance of your databases and expert advice for performance optimization and tuning. You can't get application performance without database performance. Give everyone on the team a comprehensive view of how every aspect of the system affects performance across SQL database operations, host server and OS, virtualization resources and storage I/O. Quickly find bottlenecks and troubleshoot complex problems.
The many IoT deployments around the world are busy integrating smart devices and sensors into their enterprise IT infrastructures. Yet all of this technology – and there are an amazing number of choices – is of no use without the software to gather, communicate, and analyze the new data flows. Without software, there is no IT. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, Dave McCarthy, Director of Products at Bsquare Corporation; Alan Williamson, Principal...
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
"This is specifically designed to accommodate some of the needs for high availability and failover in a network managed system for the major Korean corporations," stated Thomas Masters, Managing Director at InfranicsUSA, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"Qosmos has launched L7Viewer, a network traffic analysis tool, so it analyzes all the traffic between the virtual machine and the data center and the virtual machine and the external world," stated Sebastien Synold, Product Line Manager at Qosmos, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"Coalfire is a cyber-risk, security and compliance assessment and advisory services firm. We do a lot of work with the cloud service provider community," explained Ryan McGowan, Vice President, Sales (West) at Coalfire Systems, Inc., in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life sett...
An IoT product’s log files speak volumes about what’s happening with your products in the field, pinpointing current and potential issues, and enabling you to predict failures and save millions of dollars in inventory. But until recently, no one knew how to listen. In his session at @ThingsExpo, Dan Gettens, Chief Research Officer at OnProcess, discussed recent research by Massachusetts Institute of Technology and OnProcess Technology, where MIT created a new, breakthrough analytics model for ...